Search Results - "Pearson, Andrew"

Cancer research in Europe: a focus on children and young people by Vassal, Gilles, Pearson, Andrew D J

“…[...]of clinical research, integration of care and research, and academic cooperative groups linking clinical with basic and translational research during the…”
Get full text

Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project by BRISSE, Hervé J, MCCARVILLE, M. Beth, LEWINGTON, Valerie J, SARNACKI, Sabine, HERO, Barbara, KANEKO, Michio, LONDON, Wendy B, PEARSON, Andrew D. J, COHN, Susan L, MONCLAIR, Tom, GRANATA, Claudio, BARBARA KRUG, K, WOOTTON-GORGES, Sandra L, KANEGAWA, Kimio, GIAMMARILE, Francesco, SCHMIDT, Matthias, SHULKIN, Barry L, MATTHAY, Katherine K

“…Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the…”
Get full text

Advances in Risk Classification and Treatment Strategies for Neuroblastoma by Pinto, Navin R, Applebaum, Mark A, Volchenboum, Samuel L, Matthay, Katherine K, London, Wendy B, Ambros, Peter F, Nakagawara, Akira, Berthold, Frank, Schleiermacher, Gudrun, Park, Julie R, Valteau-Couanet, Dominique, Pearson, Andrew D J, Cohn, Susan L

“…Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and…”
Get full text

New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK by BARONE, Giuseppe, ANDERSON, John, PEARSON, Andrew D. J, PETRIE, Kevin, CHESLER, Louis

“…Clinical outcome remains poor in patients with high-risk neuroblastoma, in which chemoresistant relapse is common following high-intensity conventional…”
Get full text

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report by COHN, Susan L, PEARSON, Andrew D. J, MOSSERI, Veronique, SIMON, Thorsten, GARAVENTA, Alberto, CASTEL, Victoria, MATTHAY, Katherine K, LONDON, Wendy B, MONCLAIR, Tom, AMBROS, Peter F, BRODEUR, Garrett M, FALDUM, Andreas, HERO, Barbara, IEHARA, Tomoko, MACHIN, David

“…Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is…”
Get full text

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial by Ladenstein, Ruth, Pötschger, Ulrike, Valteau-Couanet, Dominique, Luksch, Roberto, Castel, Victoria, Yaniv, Isaac, Laureys, Genevieve, Brock, Penelope, Michon, Jean Marie, Owens, Cormac, Trahair, Toby, Chan, Godfrey Chi Fung, Ruud, Ellen, Schroeder, Henrik, Beck Popovic, Maja, Schreier, Guenter, Loibner, Hans, Ambros, Peter, Holmes, Keith, Castellani, Maria Rita, Gaze, Mark N, Garaventa, Alberto, Pearson, Andrew D J, Lode, Holger N

“…Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and…”
Get full text

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors by Geoerger, Birgit, Bourdeaut, Franck, DuBois, Steven G, Fischer, Matthias, Geller, James I, Gottardo, Nicholas G, Marabelle, Aurélien, Pearson, Andrew D J, Modak, Shakeel, Cash, Thomas, Robinson, Giles W, Motta, Marlyane, Matano, Alessandro, Bhansali, Suraj G, Dobson, Jason R, Parasuraman, Sudha, Chi, Susan N

“…The cyclin-dependent kinase (CDK) 4/6 inhibitor, ribociclib (LEE011), displayed preclinical activity in neuroblastoma and malignant rhabdoid tumor (MRT)…”
Get full text

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project by LONDON, Wendy B, CASTEL, Victoria, MATTHAY, Katherine K, MONCLAIR, Tom, AMBROS, Peter F, PEARSON, Andrew D. J, COHN, Susan L, BERTHOLD, Frank, NAKAGAWARA, Akira, LADENSTEIN, Ruth L, IEHARA, Tomoko

“…Survival after neuroblastoma relapse is poor. Understanding the relationship between clinical and biologic features and outcome after relapse may help in…”
Get full text

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report by MONCLAIR, Tom, BRODEUR, Garrett M, VON SCHWEINITZ, Dietrich, SIMON, Thorsten, COHN, Susan L, PEARSON, Andrew D. J, AMBROS, Peter F, BRISSE, Hervé J, CECCHETTO, Giovanni, HOLMES, Keith, KANEKO, Michio, LONDON, Wendy B, MATTHAY, Katherine K, NUCHTERN, Jed G

“…The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification…”
Get full text

Conjugated Small Molecule for Efficient Hole Transport in High‐Performance p‐i‐n Type Perovskite Solar Cells by Yang, Liyan, Cai, Feilong, Yan, Yu, Li, Jinghai, Liu, Dan, Pearson, Andrew J., Wang, Tao

“…The π‐conjugated organic small molecule 4,4′‐cyclohexylidenebis[N,N‐bis(4‐methylphenyl) benzenamine] (TAPC) has been explored as an efficient hole transport…”
Get full text

Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors by Skinner, Roderick, Parry, Annie, Price, Lisa, Cole, Michael, Craft, Alan W, Pearson, Andrew D.J

“…Abstract Purpose The long-term outcome of platinum-induced nephrotoxicity is unknown. This prospective single-centre longitudinal cohort study evaluated…”
Get full text

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma by Berry, Teeara, Luther, William, Bhatnagar, Namrata, Jamin, Yann, Poon, Evon, Sanda, Takaomi, Pei, Desheng, Sharma, Bandana, Vetharoy, Winston R, Hallsworth, Albert, Ahmad, Zai, Barker, Karen, Moreau, Lisa, Webber, Hannah, Wang, Wenchao, Liu, Qingsong, Perez-Atayde, Antonio, Rodig, Scott, Cheung, Nai-Kong, Raynaud, Florence, Hallberg, Bengt, Robinson, Simon P, Gray, Nathanael S, Pearson, Andrew D J, Eccles, Suzanne A, Chesler, Louis, George, Rani E

“…The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we…”
Get full text

Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project by Sokol, Elizabeth, Desai, Ami V, Applebaum, Mark A, Valteau-Couanet, Dominique, Park, Julie R, Pearson, Andrew D J, Schleiermacher, Gudrun, Irwin, Meredith S, Hogarty, Michael, Naranjo, Arlene, Volchenboum, Samuel, Cohn, Susan L, London, Wendy B

“…The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and…”
Get full text

MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature by Gaspar, Nathalie, Marshall, Lynley, Perryman, Lara, Bax, Dorine A., Little, Suzanne E., Pereira, Marta Sofia Carvalho Ribeiro Viana, Sharp, Swee Y., Vassal, Gilles, Pearson, Andrew D. J., Reis, R. M., Hargrave, Darren, Workman, Paul, Jones, Chris

“…Sensitivity to temozolomide is restricted to a subset of glioblastoma patients, with the major determinant of resistance being a lack of promoter methylation…”
Get full text

Maximizing and stabilizing luminescence from halide perovskites with potassium passivation by Abdi-Jalebi, Mojtaba, Andaji-Garmaroudi, Zahra, Cacovich, Stefania, Stavrakas, Camille, Philippe, Bertrand, Richter, Johannes M., Alsari, Mejd, Booker, Edward P., Hutter, Eline M., Pearson, Andrew J., Lilliu, Samuele, Savenije, Tom J., Rensmo, Håkan, Divitini, Giorgio, Ducati, Caterina, Friend, Richard H., Stranks, Samuel D.

“…Modifying the surfaces and grain boundaries of perovskites with passivating potassium halide layers can mitigate non-radiative losses and photoinduced ion…”
Get full text

ACCELERATE – Five years accelerating cancer drug development for children and adolescents by Pearson, Andrew D.J., Weiner, Susan L., Adamson, Peter C., Karres, Dominik, Reaman, Gregory, Rousseau, Raphaël, Blanc, Patricia, Norga, Koen, Skolnik, Jeffrey, Kearns, Pam, Scobie, Nicole, Barry, Elly, Marshall, Lynley V., Knox, Leona, Caron, Hubert, Wariabharaj, Darshan, Pappo, Alberto, DuBois, Steven G., Gore, Lia, Kieran, Mark, Weigel, Brenda, Fox, Elizabeth, Nysom, Karsten, de Rojas, Teresa, Vassal, Gilles

“…Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving survival and reducing long-term side-effects for children and…”
Get full text

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration by Pearson, Andrew D J, Barry, Elly, Mossé, Yael P, Ligas, Franca, Bird, Nick, de Rojas, Teresa, Zimmerman, Zachary F, Wilner, Keith, Woessmann, Willi, Weiner, Susan, Weigel, Brenda, Venkatramani, Rajkumar, Valteau, Dominique, Trahair, Toby, Smith, Malcolm, Singh, Sonia, Selvaggi, Giovanni, Scobie, Nicole, Schleiermacher, Gudrun, Richardson, Nicholas, Park, Julie, Nysom, Karsten, Norga, Koen, Merino, Margret, McDonough, Joe, Matloub, Yousif, Marshall, Lynley V, Lowe, Eric, Lesa, Giovanni, Irwin, Meredith, Karres, Dominik, Gajjar, Amar, Doz, François, Fox, Elizabeth, DuBois, Steven G, Donoghue, Martha, Casanova, Michela, Caron, Hubert, Buenger, Vickie, Bradford, Diana, Blanc, Patricia, Barone, Amy, Reaman, Gregory, Vassal, Gilles

“…The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums focused on anaplastic lymphoma kinase (ALK) inhibition in paediatric…”
Get full text

Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project by Moroz, Veronica, Machin, David, Faldum, Andreas, Hero, Barbara, Iehara, Tomoko, Mosseri, Veronique, Ladenstein, Ruth, Bernardi, Bruno De, Rubie, Hervé, Berthold, Frank, Matthay, Katherine K, Monclair, Tom, Ambros, Peter F, Pearson, Andrew D.J, Cohn, Susan L, London, Wendy B

“…Abstract Purpose Increasing age has been an adverse risk factor in children with neuroblastoma (NB) since the 1970’s, with a 12-month age-at-diagnosis cut-off…”
Get full text

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database by Morgenstern, Daniel A, London, Wendy B, Stephens, Derek, Volchenboum, Samuel L, Simon, Thorsten, Nakagawara, Akira, Shimada, Hiroyuki, Schleiermacher, Gudrun, Matthay, Katherine K, Cohn, Susan L, Pearson, Andrew D.J, Irwin, Meredith S

“…Abstract Neuroblastoma is a childhood cancer with remarkably divergent tumour behaviour and the presence of metastatic disease is a powerful predictor of…”
Get full text

Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective by Moreno, Lucas, Pearson, Andrew D. J., Paoletti, Xavier, Jimenez, Irene, Geoerger, Birgit, Kearns, Pamela R., Zwaan, C. Michel, Doz, Francois, Baruchel, Andre, Vormoor, Josef, Casanova, Michela, Pfister, Stefan M., Morland, Bruce, Vassal, Gilles

“…Precision medicine has dramatically changed the landscape of drug development in oncology, but this paradigm shift remains to be adopted in early phase…”
Get full text